セルジェンテック株式会社
Chiba, JP · 1 known investors
CellGenTech develops ex-vivo gene therapy products using gene-transduced human adipose cells (GMAC) to treat rare diseases such as familial LCAT deficiency, Fabry disease, and hemophilia. The Japanese biotech company works with academic and pharmaceutical partners on regenerative medicine products and also holds cell-preservation solution technology.
Founders & leadership
麻
麻生雅是代表取締役社長 (President & CEO)
Investors · 1
Frequently asked questions
- What does セルジェンテック株式会社 do?
- CellGenTech develops ex-vivo gene therapy products using gene-transduced human adipose cells (GMAC) to treat rare diseases such as familial LCAT deficiency, Fabry disease, and hemophilia. The Japanese biotech company works with academic and pharmaceutical partners on regenerative medicine products and also holds cell-preservation solution technology.
- Who are セルジェンテック株式会社's investors?
- セルジェンテック株式会社's investors include Medical Incubator Japan K.K..
- Where is セルジェンテック株式会社 headquartered?
- セルジェンテック株式会社 is headquartered in Chiba, JP.